Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.

Area of Focus

Maps and Interactives

January 19, 2021

Average Employee Premium Contribution and Deductible as Percent of Median Household Income, by State, 2019

Publication Details

Date

January 19, 2021

Area of Focus

Controlling Health Care Costs

Topics

Coverage and Access

Advanced Search

Advanced Search

Filter your query

Publication Types

Other

Average Employee Premium Contribution and Deductible as Percent of Median Household Income, by State, 2019

Publication Types

Other

Average Employee Premium Contribution and Deductible as Percent of Median Household Income, by State, 2019

Related Content

Domestic Reference Pricing and Its Potential Role in Medicare Pharmaceutical Price Negotiations

Skinny Labeling: A Pathway for Timely Generic Drug Competition

Policymakers’ Attention Turns to Drug Patents in the Debate on Prices